Profile data is unavailable for this security.
About the company
Align Technology, Inc. designs, manufactures and markets Invisalign clear aligners and iTero intraoral scanners and services for dentistry, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for dental laboratories and dental practitioners. It operates through two segments: Clear Aligner segment and Imaging Systems and CAD/CAM services (Systems and Services) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Invisalign Moderate, Lite and Express packages and Invisalign Go (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case). The Systems and Services segment consists of its iTero intraoral scanning systems, which includes a hardware platform and restorative or orthodontic software options, OrthoCAD services and ancillary products, as well as exocad’s CAD/CAM software solution.
- Revenue in USD (TTM)3.47bn
- Net income in USD698.45m
- Incorporated1997
- Employees18.07k
- LocationAlign Technology Inc410 NORTH SCOTTSDALE ROAD, SUITE 1300TEMPE 85281United StatesUSA
- Phone+1 (408) 470-1000
- Fax+1 (408) 470-1010
- Websitehttp://www.aligntech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| West Pharmaceutical Services Inc. | 2.52bn | 519.20m | 31.24bn | 9.20k | 61.71 | 15.37 | 51.12 | 12.38 | 6.84 | 6.84 | 33.22 | 27.47 | 0.9473 | 4.93 | 6.14 | 274,184.80 | 18.63 | 11.01 | 22.16 | 13.01 | 39.35 | 33.28 | 19.67 | 12.68 | 2.39 | 72.83 | 0.1111 | 18.33 | 16.69 | 8.93 | 43.24 | 29.35 | 5.79 | 7.63 |
| Zimmer Biomet Holdings Inc | 7.89bn | 931.90m | 31.50bn | 20.00k | 33.81 | 2.50 | 15.79 | 3.99 | 4.46 | 4.39 | 37.70 | 60.27 | 0.3296 | 0.9205 | 6.35 | 394,445.00 | 3.91 | 0.9027 | 4.38 | 1.01 | 70.66 | 70.93 | 11.86 | 2.99 | 0.9643 | 6.30 | 0.3843 | 85.08 | -12.00 | 3.21 | -117.62 | -- | -1.16 | 1.76 |
| ResMed Inc. | 3.20bn | 474.51m | 38.32bn | 7.97k | 81.23 | 13.28 | 60.40 | 11.99 | 3.24 | 3.24 | 21.87 | 19.81 | 0.6864 | 3.10 | 5.76 | 401,107.30 | 10.19 | 11.98 | 12.17 | 14.03 | 57.69 | 57.66 | 14.84 | 17.49 | 1.23 | 26.34 | 0.1851 | 45.57 | 8.11 | 11.70 | -23.67 | 6.13 | 11.49 | 5.39 |
| Baxter International Inc | 12.20bn | 1.12bn | 40.72bn | 50.00k | 37.35 | 4.79 | 20.44 | 3.34 | 2.18 | 2.18 | 23.74 | 16.99 | 0.6231 | 3.71 | 6.25 | 243,940.00 | 5.78 | 10.83 | 6.89 | 13.31 | 39.57 | 41.88 | 9.27 | 17.19 | 1.78 | 12.87 | 0.4195 | 20.45 | 2.74 | 3.21 | 36.56 | 22.90 | -4.89 | -5.54 |
| Align Technology, Inc. | 3.47bn | 698.45m | 47.37bn | 18.07k | 68.32 | 13.98 | 59.27 | 13.63 | 8.77 | 8.77 | 43.66 | 42.87 | 0.7375 | 5.77 | 5.42 | 192,265.80 | 14.83 | 29.32 | 20.59 | 42.44 | 74.27 | 73.28 | 20.10 | 33.47 | 1.21 | -- | 0.00 | 0.00 | 2.71 | 23.93 | 301.08 | 65.27 | 23.72 | -- |
| DexCom, Inc. | 2.17bn | 530.60m | 54.96bn | 5.50k | 106.39 | 27.50 | 89.55 | 25.33 | 5.34 | 5.34 | 21.82 | 20.66 | 0.5407 | 2.69 | 5.56 | 394,527.30 | 13.22 | 5.78 | 15.11 | 6.78 | 69.96 | 66.09 | 24.45 | 7.98 | 5.25 | 4.02 | 0.4695 | 0.00 | 30.54 | 36.81 | 388.23 | -- | 42.98 | -- |
| Boston Scientific Corporation | 11.20bn | 526.00m | 63.89bn | 38.00k | 122.01 | 4.00 | 39.24 | 5.71 | 0.3678 | 0.3678 | 7.83 | 11.21 | 0.3613 | 2.55 | 7.15 | 294,657.90 | 1.88 | 3.03 | 2.13 | 3.78 | 66.45 | 69.70 | 5.21 | 7.17 | 1.31 | -- | 0.3636 | 0.00 | -7.66 | 5.80 | -119.23 | -- | 0.3484 | -- |
| Becton Dickinson and Co | 19.90bn | 1.87bn | 70.78bn | 72.00k | 38.71 | 2.93 | 17.28 | 3.56 | 6.37 | 6.37 | 67.88 | 84.04 | 0.3675 | 3.56 | 9.77 | 276,333.30 | 3.61 | 2.43 | 4.14 | 2.77 | 47.27 | 46.94 | 9.83 | 6.78 | 0.8506 | 7.40 | 0.4236 | 80.41 | -1.00 | 10.73 | -25.68 | 1.99 | 5.05 | 5.66 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2021 | 6.51m | 8.24% |
| Edgewood Management LLCas of 30 Jun 2021 | 4.47m | 5.66% |
| BlackRock Fund Advisorsas of 30 Jun 2021 | 3.60m | 4.56% |
| SSgA Funds Management, Inc.as of 30 Jun 2021 | 2.98m | 3.77% |
| Sands Capital Management LLCas of 30 Jun 2021 | 2.89m | 3.66% |
| Wellington Management Co. LLPas of 30 Jun 2021 | 1.89m | 2.39% |
| AllianceBernstein LPas of 30 Jun 2021 | 1.65m | 2.09% |
| Polen Capital Management LLCas of 30 Jun 2021 | 1.63m | 2.07% |
| Janus Capital Management LLCas of 30 Jun 2021 | 1.46m | 1.85% |
| JPMorgan Investment Management, Inc.as of 30 Jun 2021 | 1.46m | 1.85% |
